These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 564436)

  • 1. Differential reduction of morphine-withdrawal body shakes by butaclamol enantiomers.
    Hynes MD; McCarten MD; Shearman G; Lal H
    Life Sci; 1978 Jan; 22(1):133-6. PubMed ID: 564436
    [No Abstract]   [Full Text] [Related]  

  • 2. Stereospecific blockade of alpha 2-adrenoceptors by (+)-butaclamol: implications for the characterization of dopamine receptors.
    Spedding M; Berg C
    J Pharm Pharmacol; 1982 Jan; 34(1):56-8. PubMed ID: 6174723
    [No Abstract]   [Full Text] [Related]  

  • 3. RP 67580, a selective antagonist of neurokinin-1 receptors, modifies some of the naloxone-precipitated morphine withdrawal signs in rats.
    Maldonado R; Girdlestone D; Roques BP
    Neurosci Lett; 1993 Jun; 156(1-2):135-40. PubMed ID: 7692360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of butaclamol enantiomers on hypothalamic tyrosine hydroxylase in the rat brain].
    Mineeva MF; Raevskiĭ KS
    Biull Eksp Biol Med; 1984 Oct; 98(10):453-6. PubMed ID: 6208950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropeptide Y attenuates naloxone-precipitated morphine withdrawal via Y5-like receptors.
    Woldbye DP; Klemp K; Madsen TM
    J Pharmacol Exp Ther; 1998 Feb; 284(2):633-6. PubMed ID: 9454808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between the in vivo and an in vitro expression of opiate withdrawal precipitated by naloxone: their antagonism by l-(-)-delta9-tetrahydrocannabinol.
    Frederickson RC; Hewes CR; Aiken JW
    J Pharmacol Exp Ther; 1976 Nov; 199(2):375-84. PubMed ID: 988178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Afobazole decreases severity of morphine withdrawal syndrome: experimental evidence].
    Konstantinopol'skiĭ MA; Cherniakova IV
    Eksp Klin Farmakol; 2011; 74(10):12-6. PubMed ID: 22238980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calmodulin release from striatal membranes after acute and chronic treatment with butaclamol.
    Gnegy ME; Lau YS
    Adv Biochem Psychopharmacol; 1980; 24():147-51. PubMed ID: 6157308
    [No Abstract]   [Full Text] [Related]  

  • 9. Height-dependent difference in the expression of naloxone-induced withdrawal jumping behavior in morphine dependent rats.
    Azizi H; Ranjbar-Slamloo Y; Semnanian S
    Neurosci Lett; 2012 May; 515(2):174-6. PubMed ID: 22465245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of calcium channel blockers and stimulants on morphine withdrawal in vitro.
    Barrios M; Baeyens JM
    Eur J Pharmacol; 1988 Jul; 152(1-2):175-8. PubMed ID: 2463173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement by haloperidol of the locomotor response induced by naloxone in morphine-treated guinea pigs.
    Chahl LA; Kavanagh CA; Corlis A
    Neurosci Lett; 1989 Jan; 96(2):213-7. PubMed ID: 2927723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of quasi-morphine withdrawal syndrome in adenosine A2A receptor knockout mice.
    Bilbao A; Cippitelli A; Martín AB; Granado N; Ortiz O; Bezard E; Chen JF; Navarro M; Rodríguez de Fonseca F; Moratalla R
    Psychopharmacology (Berl); 2006 Apr; 185(2):160-8. PubMed ID: 16470403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of clonidine on morphine withdrawal signs in the rat.
    Tseng LF; Loh HH; Wei ET
    Eur J Pharmacol; 1975 Jan; 30(1):93-9. PubMed ID: 1168138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of the stereoisomers of butaclamol on neurotensin content in discrete regions of the rat brain.
    Bissette G; Dauer WT; Kilts CD; O'Connor L; Nemeroff CB
    Neuropsychopharmacology; 1988 Dec; 1(4):329-35. PubMed ID: 2472151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of chlorine substituents on the benzene rings of an analogue of the antipsychotic drug butaclamol on the interaction with dopamine and muscarinic receptors in rat brain.
    Pugsley TA; Lippmann W
    J Pharm Pharmacol; 1979 Jan; 31(1):47-9. PubMed ID: 32368
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of beta-adrenoceptors in the expression of morphine withdrawal signs.
    Funada M; Suzuki T; Sugano Y; Tsubai M; Misawa M; Ueda H; Misu Y
    Life Sci; 1994; 54(8):PL113-8. PubMed ID: 7509021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereospecific antagonism by d-butaclamol of dopamine-induced relaxation of the isolated rabbit mesenteric artery.
    Brodde OE; Freistühler J; Meyer FJ
    J Cardiovasc Pharmacol; 1981; 3(4):828-37. PubMed ID: 6167812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of nociceptin(1-17) fragments and its tyrosine-substituted derivative on morphine-withdrawal signs in rats.
    Kotlinska J; Dylag T; Rafalski P; Talarek S; Kosior M; Silberring J
    Neuropeptides; 2004 Oct; 38(5):277-82. PubMed ID: 15464192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic mechanisms in precipitated withdrawal in morphine-dependent rats.
    Ary M; Cox B; Lomax P
    J Pharmacol Exp Ther; 1977 Feb; 200(2):271-6. PubMed ID: 557107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic treatment with ascorbic acid inhibits the morphine withdrawal response in guinea-pigs.
    Johnston PA; Chahl LA
    Neurosci Lett; 1992 Jan; 135(1):23-7. PubMed ID: 1542433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.